Last reviewed · How we verify
NCT03966079: STEP
Thrombolysis Endovascular Treatment of Pulmonary Embolism
Phase 3 trial testing recombinant tissue plasminogen activator in Pulmonary Embolism in 50 participants. Completed in 31 January 2020.
31 January 2020
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 2017 |
| Primary completion | 31 January 2020 |
| Estimated completion | 31 January 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- recombinant tissue plasminogen activator — full drug profile →
Conditions studied
- Pulmonary Embolism — all drugs for Pulmonary Embolism →
- Acute Pulmonary Embolism — all drugs for Acute Pulmonary Embolism →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
18 and older, any sex, with Pulmonary Embolism or Acute Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with right ventricular dysfunction with single-dose rtPA
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03966079
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of recombinant tissue plasminogen activator
Trials testing the same drug.
- NCT05155540 — Direct Mechanical Thrombectomy Versus Bridging Therapy · Phase 4 · completed
- NCT01513759 — Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy · Phase 3 · completed
Other recruiting trials for Pulmonary Embolism
Currently open trials in the same condition.
- NCT07381712 — High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism. · NA · active not recruiting
- NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
- NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism · recruiting
- NCT06600542 — Inari VISION Registry · recruiting
- NCT06622876 — Incidental Discovery of Pulmonary Emboli Via CT Scan: Impact of Detections on Patient Care and Resulting Complications · recruiting
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03966079 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 30 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966079.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing